Manufacturing

Articles

BMS changes its US geographic footprint with R&D investments and closures.

Bristol-Myers Squibb Announces US Investments and Closures

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Biosimilars may be the key to CMO growth.

Biosimilars Supporting Contract Manufacturers’ Growth

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Takeda Builds Dengue Vaccine Manufacturing Plant in Germany

Avecia is adding drug substance capacity at its Milford, MA manufacturing site.

Nitto Avecia Expands Oligonucleotide Manufacturing Capacity

German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.

ARTES and BioSun Collaborate on HPV Vaccine

Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.

Astellas to Acquire Ganymed

The Koolit Advanced PCM Gel from Cold Chain Technologies provides cold-temperature protection for drugs and vaccines during transport.

Solid Phase-Change Material Provides Safe Cold Chain Shipment

Sean Milmo is a freelance writer based in Essex, UK.

Regulators are tightening up on post-marketing monitoring of biological medicines to detect deficiencies caused by manufacturing problems, particularly those stemming from post-authorization changes in the manufacturing process.

Pharmacovigilance of Biologics Under Scrutiny

Ravi Limaye gives an overview of the biosimilar industry and projects for 2020.

Outlook for Biosimilars in 2020

Aptar Pharma has signed a license agreement with BD to jointly develop and bring a new autoinjector to market.

Manufacturing, Biologic Drugs